NCT07298889 High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS
| NCT ID | NCT07298889 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chongqing Medical University |
| Condition | Noninvasive Ventilation |
| Study Type | INTERVENTIONAL |
| Enrollment | 706 participants |
| Start Date | 2026-01-04 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 706 participants in total. It began in 2026-01-04 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * PaO2/FiO2 ≤300 mmHg or SpO2/FiO2 ≤315（SpO2 ≤97%) * Anticipated NIV duration \> 12 h * Preserved consciousness (GCS≥13) Exclusion Criteria: * Use of NIV \> 24 h before randomization * Acute-on-chronic respiratory failure * Congestive heart failure * Use of NIV after extubation (within 48 hours) * Contraindications to NIV (e.g., anatomical malformations, recent pulmonary/esophageal surgery \[within 7 days\]) * Pneumothorax * NIV intolerance * Refusal to participate * Pregnancy * Need for emergency intubation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07298889 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Noninvasive Ventilation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07298889 currently recruiting?
Yes, NCT07298889 is actively recruiting participants. Contact the research team at 1062914316@qq.com for enrollment information.
Where is the NCT07298889 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT07298889 clinical trial?
NCT07298889 is sponsored by Chongqing Medical University. The trial plans to enroll 706 participants.